Anemia, a condition characterized by a decrease in the number of red blood cells or less than the normal quantity of hemoglobin in the blood, presents a diagnostic challenge due to its diverse etiologies and clinical presentations. This article aims to provide a comprehensive guide to the diagnostic approach for anemia in clinical practice.
A thorough patient history and physical examination provide vital clues to the potential cause of anemia. A detailed dietary history, family history of hematological disorders, and inquiries about symptoms like fatigue, pallor, and dyspnea are essential. Physical examination should include assessment for jaundice, pallor, and signs of underlying systemic diseases.
Initial laboratory investigations should include complete blood count (CBC) and reticulocyte count. The mean corpuscular volume (MCV) can categorize anemia into microcytic, normocytic, or macrocytic, guiding further investigations. Reticulocyte count helps differentiate between underproduction and increased destruction or loss of red blood cells. Additional tests like iron studies, vitamin B12, and folate levels are guided by these results.
When basic investigations do not provide a clear etiology, advanced diagnostic tools can be employed. Bone marrow biopsy can be considered in cases of unexplained normocytic or macrocytic anemia. Hemoglobin electrophoresis is useful in suspected cases of hemoglobinopathies. Genetic testing can also be considered in certain cases.
Anemia is a complex disorder with multiple potential etiologies. A systematic approach to diagnosis, beginning with a detailed history and physical examination, followed by targeted laboratory investigations and, if necessary, advanced diagnostic tools, can help clinicians accurately diagnose and manage this condition. Continuous research and advancements in diagnostic modalities promise to further enhance our understanding and management of anemia.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation